Urofollitrophin is administered via subcutaneous or intramuscular injection to stimulate the development of multiple ovarian follicles. This increases the probability that at least one follicle will mature and be ready for fertilization. In most treatment cycles, urofollitrophin is combined with human chorionic gonadotropin (hCG), which induces ovulation approximately 38–40 hours after administration.

Continuous medical monitoring is essential to adjust dosages appropriately and reduce the risk of ovarian overstimulation.

Urofollitrophin is particularly beneficial for women who:

• Do not respond to first-line treatments such as clomiphene citrate
• Have hormonal imbalances resulting in low FSH levels
• Have undergone ovarian surgery
• Experience infertility due to premature ovarian failure

Its strong ovulation-inducing success rate makes urofollitrophin a cornerstone of fertility programs worldwide.

Urofollitrophin is generally well tolerated. Most side effects are mild and temporary, including:

• Injection site inflammation
• Abdominal bloating or discomfort
• Mood fluctuations

Although rare, serious complications such as ovarian hyperstimulation syndrome (OHSS) may occur, particularly when multiple follicles develop. Careful medical supervision is critical to prevent severe outcomes including ovarian rupture, thrombosis, or fluid accumulation.

Urofollitrophin has transformed the lives of countless women by helping them achieve ovulation, conceive, and build families. When administered under professional medical guidance with routine monitoring, it offers a safe, reliable, and effective solution for a wide range of reproductive challenges.